Michael Barbella, Managing Editor01.19.24
Biocomposites has opened a new sales and distribution office in Italy (Biocomposites SRL) to commercialize its STIMULAN, NanoBone, genex and SYNICEM Spacer products.
STIMULAN, the only calcium sulfate antibiotic carrier to be approved for use in bone and soft tissue, is an important tool used by Italian surgeons to help manage infection cases. The opening of a new sales and distribution office in Prato, near Florence—along with the recruitment of highly trained specialists to promote and support the products—will deliver a more direct relationship and higher service level between Biocomposites and its Italian customers, according to the company.
"Strengthening our Italian operation is part of Biocomposites' successful strategy of growing the company by expanding its presence in markets across the world," Biocomposites CEO Michael Harris stated. "With our portfolio of products for use in bone and soft tissue available in Italy, it was an important next step for us to open a sales and distribution office to support our customers there. Over the coming months, I look forward to seeing these products helping more surgeons and their patients."
Led by General Manager Pierluigi Leone, the sales team will continue to work with local agents to fulfil tenders and introduce the broader Biocomposites portfolio to surgeons and hospitals throughout Italy.
"This is an exciting time for Biocomposites Italy," Leone said. "We have established an experienced team, incorporated Biocomposites SRL, and set up our new distribution center in only a few months. We are already providing surgeons with our products. I look forward to developing and expanding our team."
Biocomposites is an international medical devices company that engineers, manufactures, and markets products for use in infection management in bone and soft tissue. Based in Keele, United Kingdom, it has global operations across Europe, United States, Argentina, Canada, China, and India. Biocomposites develops calcium compounds and bone cements for surgical use. Its products regenerate bone and target infection risks across various specialties, including musculoskeletal infection, orthopedics, trauma, spine, foot and ankle, podiatry, and sports injuries. Biocomposites products are now used in more than 1 million procedures annually and sold in over 100 countries worldwide.
STIMULAN, the only calcium sulfate antibiotic carrier to be approved for use in bone and soft tissue, is an important tool used by Italian surgeons to help manage infection cases. The opening of a new sales and distribution office in Prato, near Florence—along with the recruitment of highly trained specialists to promote and support the products—will deliver a more direct relationship and higher service level between Biocomposites and its Italian customers, according to the company.
"Strengthening our Italian operation is part of Biocomposites' successful strategy of growing the company by expanding its presence in markets across the world," Biocomposites CEO Michael Harris stated. "With our portfolio of products for use in bone and soft tissue available in Italy, it was an important next step for us to open a sales and distribution office to support our customers there. Over the coming months, I look forward to seeing these products helping more surgeons and their patients."
Led by General Manager Pierluigi Leone, the sales team will continue to work with local agents to fulfil tenders and introduce the broader Biocomposites portfolio to surgeons and hospitals throughout Italy.
"This is an exciting time for Biocomposites Italy," Leone said. "We have established an experienced team, incorporated Biocomposites SRL, and set up our new distribution center in only a few months. We are already providing surgeons with our products. I look forward to developing and expanding our team."
Biocomposites is an international medical devices company that engineers, manufactures, and markets products for use in infection management in bone and soft tissue. Based in Keele, United Kingdom, it has global operations across Europe, United States, Argentina, Canada, China, and India. Biocomposites develops calcium compounds and bone cements for surgical use. Its products regenerate bone and target infection risks across various specialties, including musculoskeletal infection, orthopedics, trauma, spine, foot and ankle, podiatry, and sports injuries. Biocomposites products are now used in more than 1 million procedures annually and sold in over 100 countries worldwide.